Skip to main content
. 2024 Feb 25;115(4):1296–1305. doi: 10.1111/cas.16107

FIGURE 4.

FIGURE 4

Swimmer plot showing (A) Duration of tepotinib treatment and best overall response and (B) duration of tepotinib treatment and timing of adverse events in Japanese patients. 1L, first line; 2L+, second‐or‐later line; A, age; AE, adverse event; ALT, alanine transaminase; AST, aspartate transaminase; BOR, best overall response; H, histology; L, line of therapy; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.